Isabelle Tabah-Fisch

9.1k total citations · 2 hit papers
23 papers, 4.6k citations indexed

About

Isabelle Tabah-Fisch is a scholar working on Oncology, Pathology and Forensic Medicine and Genetics. According to data from OpenAlex, Isabelle Tabah-Fisch has authored 23 papers receiving a total of 4.6k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 7 papers in Pathology and Forensic Medicine and 4 papers in Genetics. Recurrent topics in Isabelle Tabah-Fisch's work include Colorectal Cancer Treatments and Studies (6 papers), Cancer Treatment and Pharmacology (6 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Isabelle Tabah-Fisch is often cited by papers focused on Colorectal Cancer Treatments and Studies (6 papers), Cancer Treatment and Pharmacology (6 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Isabelle Tabah-Fisch collaborates with scholars based in France, Belgium and United States. Isabelle Tabah-Fisch's co-authors include Thierry André, Aimery de Gramont, John Bridgewater, Matilde Navarro, Philip R. Clingan, C. Boni, Marta Zaninelli, Josep Tabernero, Tamas Hickish and C. Topham and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Isabelle Tabah-Fisch

23 papers receiving 4.5k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer

2004 2.7k citations Thierry André, C. Boni et al. New England Journal of Medicine profile →
OPTIMOX1: A Randomized Study of FOLFOX4 or FOLFOX7 With Oxaliplatin in a Stop-and-Go Fashion in Advanced Colorectal Cancer—A GERCOR Study

2006 583 citations Christophe Tournigand, Andrés Cervantes et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Isabelle Tabah-Fisch France	13	3.7k	1.0k	983	902	504	23	4.6k
Jean‐François Morère France	31	2.5k 0.7×	1.3k 1.3×	753 0.8×	498 0.6×	180 0.4×	216	4.0k
Gabriela Kornek Austria	38	3.7k 1.0×	1.7k 1.6×	565 0.6×	1.6k 1.7×	672 1.3×	161	6.3k
Romain Coriat France	40	2.7k 0.7×	1.6k 1.6×	441 0.4×	1.3k 1.4×	485 1.0×	287	5.2k
Jacob J. Lokich United States	35	1.9k 0.5×	1.3k 1.2×	503 0.5×	961 1.1×	169 0.3×	156	4.0k
P. Kosmidis Greece	39	3.9k 1.1×	2.3k 2.3×	645 0.7×	1.0k 1.1×	157 0.3×	224	6.4k
Guido Francini Italy	28	4.1k 1.1×	1.3k 1.2×	1.1k 1.2×	934 1.0×	203 0.4×	113	5.3k
Sheryl Koski Canada	16	3.6k 1.0×	1.4k 1.4×	527 0.5×	767 0.9×	1.1k 2.2×	35	4.9k
G. Ganem France	27	3.3k 0.9×	1.1k 1.1×	1.1k 1.1×	842 0.9×	993 2.0×	68	4.5k
Jeremy Shapiro Australia	24	3.3k 0.9×	1.5k 1.4×	1.2k 1.2×	745 0.8×	632 1.3×	142	4.6k
Karen Borgonovo Italy	33	2.7k 0.7×	1.5k 1.5×	618 0.6×	667 0.7×	256 0.5×	83	3.8k

Countries citing papers authored by Isabelle Tabah-Fisch

Since Specialization

Citations

This map shows the geographic impact of Isabelle Tabah-Fisch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Isabelle Tabah-Fisch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Isabelle Tabah-Fisch more than expected).

Fields of papers citing papers by Isabelle Tabah-Fisch

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Isabelle Tabah-Fisch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Isabelle Tabah-Fisch. The network helps show where Isabelle Tabah-Fisch may publish in the future.

Co-authorship network of co-authors of Isabelle Tabah-Fisch

This figure shows the co-authorship network connecting the top 25 collaborators of Isabelle Tabah-Fisch. A scholar is included among the top collaborators of Isabelle Tabah-Fisch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Isabelle Tabah-Fisch. Isabelle Tabah-Fisch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Naour, Augustin Le, Hélène Leray, L Lemaître, et al.. (2020). Circulating CD14^high CD16^low intermediate blood monocytes as a biomarker of ascites immune status and ovarian cancer progression. Journal for ImmunoTherapy of Cancer. 8(1). e000472–e000472. 31 indexed citations

Cutsem, Eric Van, Bohuslav Melichar, Marc Van den Eynde, et al.. (2019). Phase 2 study results of murlentamab, a monoclonal antibody targeting the Anti-Mullerian-Hormone-Receptor II (AMHRII), acting through Tumor-Associated Macrophage engagement in advanced/metastatic colorectal cancers. Annals of Oncology. 30. iv153–iv154. 5 indexed citations

Léary, Alexandra, Ahmad Awada, Jean‐Pierre Delord, et al.. (2019). First-in-human first-in-class phase I trial of murlentamab, an anti-Mullerian-hormone receptor II (AMHRII) monoclonal antibody acting through tumor-associated macrophage (TAM) engagement, as single agent and in combination with carboplatin (C) and paclitaxel (P) in AMHRII-expressing advanced/metastatic gynecological cancer patients (pts).. Journal of Clinical Oncology. 37(15_suppl). 2521–2521. 1 indexed citations

Léary, Alexandra, Philippe Aftimos, Jean‐Pierre Delord, et al.. (2018). A first-in-human study of monoclonal antibody GM102 in patients with anti-Mullerian-hormone-receptor II (AMHRII) positive gynecological cancers.. Journal of Clinical Oncology. 36(15_suppl). 5542–5542. 4 indexed citations

MacBeath, Gavin, Éric Pujade-Lauraine, M.A. Higgins, et al.. (2014). A Meta-Analysis of Biomarkers in Three Randomized, Phase 2 Studies of Mm-121, a Ligand-Blocking Anti-Erbb3 Antibody, in Patients with Ovarian, Lung, and Breast Cancers. Annals of Oncology. 25. iv82–iv82. 6 indexed citations

Geslin, Claire, Céline Nicolazzi, Gabriela Garcia, et al.. (2012). 325 MM-121 (SAR256212), an Anti-ErbB3 Monoclonal Antibody, Shows Synergistic Tumor Growth Inhibition in Combination with a Pan-PI3K Inhibitor or a Microtubule Inhibitor Through ErbB3 Expression Modulation. European Journal of Cancer. 48. 99–99. 2 indexed citations

Press, Michael F., Guido Sauter, Marc Buyse, et al.. (2010). Alteration of Topoisomerase II–Alpha Gene in Human Breast Cancer: Association With Responsiveness to Anthracycline-Based Chemotherapy. Journal of Clinical Oncology. 29(7). 859–867. 146 indexed citations

Eiermann, W., Tadeusz Pieńkowski, John Crown, et al.. (2009). BCIRG 005 main efficacy analysis: a phase III randomized trial comparing docetaxel in combination with doxorubicin and cyclophosphamide (TAC) versus doxorubicin and cyclophosphamide followed by docetaxel (AC→T) in women with Her-2/neu negative axillary lymph node positive early breast cancer.. Cancer Research. 69(2_Supplement). 77–77. 23 indexed citations

Ribeiro, Raul C., Eva Steliarova‐Foucher, Ian Magrath, et al.. (2008). Baseline status of paediatric oncology care in ten low-income or mid-income countries receiving My Child Matters support: a descriptive study. The Lancet Oncology. 9(8). 721–729. 184 indexed citations

10.

Cunningham, David, Bhawna Sirohi, A Płużańska, et al.. (2008). Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer. Annals of Oncology. 20(2). 244–250. 48 indexed citations

11.

Gnaoui, Taoufik El, Jehan Dupuis, Karim Belhadj, et al.. (2007). Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy. Annals of Oncology. 18(8). 1363–1368. 121 indexed citations

12.

Gramont, Aimery de, Marc Buyse, José Cortiñas Abrahantes, et al.. (2007). Reintroduction of Oxaliplatin Is Associated With Improved Survival in Advanced Colorectal Cancer. Journal of Clinical Oncology. 25(22). 3224–3229. 103 indexed citations

13.

Roncal, Carmen, Wei Mu, Byron P. Croker, et al.. (2007). Effect of elevated serum uric acid on cisplatin-induced acute renal failure. American Journal of Physiology-Renal Physiology. 292(1). F116–F122. 102 indexed citations

14.

Sargent, Daniel J., Richard M. Goldberg, Harry Bleiberg, et al.. (2006). A pooled safety and efficacy analysis of the FOLFOX4 regimen (bi-monthly oxaliplatin plus fluorouracil/leucovorin) in elderly compared to younger patients with colorectal cancer. Journal of Clinical Oncology. 24(18_suppl). 3517–3517. 10 indexed citations

15.

Gnaoui, Taoufik El, Jehan Dupuis, Karim Belhadj, et al.. (2006). Rituximab, gemcitabine and oxaliplatin (R-GEMOX): An effective regimen for relapsed and refractory B-cell lymphoma. Journal of Clinical Oncology. 24(18_suppl). 7562–7562. 4 indexed citations

16.

Ejaz, A. Ahsan, Wei Mu, Duk‐Hee Kang, et al.. (2006). Could Uric Acid Have a Role in Acute Renal Failure?. Clinical Journal of the American Society of Nephrology. 2(1). 16–21. 149 indexed citations

17.

Goldberg, Richard M., Isabelle Tabah-Fisch, Harry Bleiberg, et al.. (2006). Pooled Analysis of Safety and Efficacy of Oxaliplatin Plus Fluorouracil/Leucovorin Administered Bimonthly in Elderly Patients With Colorectal Cancer. Journal of Clinical Oncology. 24(25). 4085–4091. 345 indexed citations

18.

André, Thierry, C. Boni, Matilde Navarro, et al.. (2004). Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer. New England Journal of Medicine. 350(23). 2343–2351. 2694 indexed citations breakdown →

19.

Gnaoui, Taoufik El, Bertrand Joly, Jehan Dupuis, et al.. (2004). Rituximab, gemcitabine and oxaliplatin (R-GEMOX): A promising regimen for refractory/relapsed B-cell lymphoma. Journal of Clinical Oncology. 22(14_suppl). 6592–6592. 1 indexed citations

20.

Dièras, Véronique, Philippe Bougnoux, Thierry Petit, et al.. (2002). Multicentre phase II study of oxaliplatin as a single-agent in cisplatin/carboplatin ± taxane-pretreated ovarian cancer patients. Annals of Oncology. 13(2). 258–266. 61 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact